Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
The Lancet (2014) - Comments
doi: 10.1016/s0140-6736(14)60958-2  issn: 0140-6736  pubmed: 25034862 

Caroline Robert, Antoni Ribas, Jedd D Wolchok, F Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S Weber, Anthony M Joshua, Wen-Jen Hwu, Tara C Gangadhar, Amita Patnaik, Roxana Dronca, Hassane Zarour, Richard W Joseph, Peter Boasberg, Bartosz Chmielowski, Christine Mateus, Michael A Postow, Kevin Gergich, Jeroen Elassaiss-Schaap